Pathophysiology and Patient Profile
Asthma: reversible airway obstruction from bronchospasm, mucosal edema, and mucus hypersecretion. Triggered by allergens, exercise, cold air, infections. Typically young, atopic. COPD: irreversible or minimally reversible obstruction from emphysema (alveolar destruction) and/or chronic bronchitis (productive cough >3 months/year for ≥2 years). Etiology: cigarette smoking (90%+), alpha-1-antitrypsin deficiency (young patients, lower lobe emphysema, non-smoker). Typically older (>40), current/ex-smoker.
Pulmonary Function Tests
Both show obstructive pattern: FEV1/FVC ratio <0.70. Severity of COPD by FEV1 % predicted: GOLD 1 (mild) ≥80%, GOLD 2 (moderate) 50–79%, GOLD 3 (severe) 30–49%, GOLD 4 (very severe) <30%. Reversibility testing (post-bronchodilator FEV1): Asthma = significant improvement (>12% and 200 mL increase in FEV1). COPD = minimal or no reversibility. Diffusing capacity (DLCO): low in emphysema (loss of alveolar surface area), normal or high in asthma and chronic bronchitis.
COPD Exacerbation Management
Short-acting beta-agonist (albuterol) + ipratropium (SABA + SAMA), systemic corticosteroids (prednisone 40 mg × 5 days — same outcome as 14 days), antibiotics if purulent sputum or increased dyspnea (azithromycin, amoxicillin-clavulanate, doxycycline). Controlled O2 — target SpO2 88–92% (hypercapnic patients lose hypoxic drive; excess O2 can worsen CO2 retention). BiPAP if pH <7.35.
Asthma Step Therapy
Step 1: SABA PRN (albuterol). Step 2: low-dose inhaled corticosteroid (ICS) + SABA PRN. Step 3: low-dose ICS + LABA. Step 4: medium-dose ICS + LABA. Step 5: high-dose ICS + LABA ± tiotropium. Step 6: add systemic corticosteroids. Biologic options (severe asthma): omalizumab (anti-IgE, allergic asthma), mepolizumab (anti-IL-5, eosinophilic asthma).